Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303051 | 0.92 | ACHE (0.42) | HTR2AACHEBCHECHRM2HTR1A | |
| SCHEMBL6306483 | 0.86 | HTR2A (0.42) | HTR2AACHEBCHECA1CA2 | |
| SCHEMBL1996543 | 0.80 | HTR2A (0.54) | HTR2AACHEBCHECA1CA2 | |
| SCHEMBL8612566 | 0.75 | HTR2A (0.39) | HTR2ACA1CA2 | |
| SCHEMBL27969025 | 0.73 | HTR2A (0.40) | HTR2AACHEBCHECA1CA2 | |
| SCHEMBL4634572 | 0.73 | GPR3 (0.38) | HTR2AACHEBCHEGPR3CHRM2 | |
| SCHEMBL3701444 | 0.72 | HTR2A (0.40) | HTR2AGPR3CYP1A2 | |
| SCHEMBL584138 | 0.72 | CA1 (0.39) | HTR2ACA1CA2 | |
| SCHEMBL8415215 | 0.71 | GPR3 (0.37) | HTR2AGPR3SLC22A2SLC22A3 | |
| SCHEMBL8744967 | 0.71 | GPR3 (0.34) | HTR2AGPR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114901391-A | System and method for producing supported catalysts | 埃克森美孚化学专利公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-112384542-A | Polyethylene composition, wire and cable and method for making the same | 埃克森美孚化学专利公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-2217627-A1 | HALOGEN SUBSTITUTED HETEROCYCLIC HETEROATOM CONTAINING LIGANDS-ALUMOXANE ACTIVATION OF METALLOCENES | ExxonMobil Chemical Patents Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2112175-A1 | Activator for metallocenes comprising one or more halogen substituted heterocyclic heteroatom containing ligand coordinated to an alumoxane | ExxonMobil Chemical Patents Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090124486-A1 | HALOGEN SUBSTITUTED HETEROCYCLIC HETEROATOM CONTAINING LIGANDS-ALUMOXANE ACTIVATION OF METALLOCENES | EXXONMOBIL CHEMICAL PATENTS INC. | 2009-05-14 | — | — | US | disclosed |
| WO-2009061678-A1 | HALOGEN SUBSTITUTED HETEROCYCLIC HETEROATOM CONTAINING LIGANDS-ALUMOXANE ACTIVATION OF METALLOCENES | EXXONMOBIL CHEMICALS PATENTS INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-6849753-B2 | Process for preparation of half-vanadocene compound | NICHIA CORPORATION (JP) | 2005-02-01 | — | — | US | disclosed |
| EP-1312610-B1 | Process for preparation of half-vanadocene compound | NICHIA CORP (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-20030109733-A1 | Process for preparation of half-vanadocene compound | UBE INDUSTRIES, LTD. (JP) | 2003-06-12 | — | — | US | disclosed |
| CN-1420118-A | Method for preparing semi-cyclopentadienyl vanadium | NICHIA KAGAKU KOGYO KK (JP) | 2003-05-28 | — | — | CN | disclosed |
| EP-1312610-A1 | Process for preparation of half-vanadocene compound | Nichia Corporation (JP) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109733-A1 | Process for preparation of half-vanadocene compound | CPNE4, VDAC2, VDAC1 | HTR2A 911/4885ACHE 3428/4885BCHE 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.